A Phase 2, Open-Label, Randomized Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus

Trial Profile

A Phase 2, Open-Label, Randomized Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Inarigivir soproxil (Primary) ; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Acronyms ACHIEVE
  • Sponsors Spring Bank Pharmaceuticals
  • Most Recent Events

    • 15 Nov 2017 According to a Spring Bank Pharmaceuticals media release, randomization of patients in the third cohort (100mg) of Part A of this trial has been initiated, and anticipates that it will release top-line results from this cohort in the second quarter of 2018. Detailed results from the second cohort (50mg) of Part A of will be presented at a future medical conferenc.
    • 15 Nov 2017 According to a Spring Bank Pharmaceuticals media release, inarigivir 50mg daily for 12 weeks met both primary endpoints of safety and efficacy in the second cohort of this trial.
    • 15 Nov 2017 Results ftom second inarigivir 50mg monotherapy dosing cohort of this trial published in a Spring Bank Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top